RECOMBINANT OR TRANSGENIC FACTOR VII COMPOUND HAVING A MAJORITY OF GLYCAN, BIANTENNARY, BISIALYLATED AND NON-FUCOSYLATED FORMS
The present invention concerns a recombinant or transgenic factor VII compound, each factor VII molecule of the compound having glycan forms linked to N-glycosylation sites, wherein among all the factor VII molecules in said compound, glycan, biantennary, bisialylated and non-fucosylated forms are in the majority. The invention also concerns such a compound for use as a medication, and a method for preparing said compound, among others.
1 . A composition of transgenic Factor VII (FVII), each molecule of Factor VII of the composition containing glycan forms bound to N-glycosylation sites, and wherein more than 50% of the glycan forms bound to N-glycosylation sites of Factor VII are biantennary, bisialylated and non fucosylated glycan forms and wherein all sialic acids of Factor VII of said composition imply α2-6-links.
2 . The composition according to claim 1 , wherein in the proportion of biantennary, bisialylated, fucosylated and non fucosylated forms is higher than 50%.
3 . The composition according to claim 1 , wherein among all the molecules of Factor VII of said composition, the proportion of fucose is comprised between 20% and 50%.
4 . The composition according to claim 2 , wherein among all the molecules of Factor VII of said composition, the proportion of fucose is comprised between 20% and 50%.
5 . The composition according to claim 1 , characterized in that said FVII is activated.
6 . The composition according to claim 1 , for use as a medicament.
7 . The use of the composition recited in any one of claims 1 to 5 , for preparing a medicament for the treatment of patients suffering from haemophilia.
8 . The use of the composition recited in any one of claims 1 to 5 , for preparing a medicament for the treatment of multiple hemorragic traumas.
9 . The use of the composition recited in any one of claims 1 to 5 , for preparing a medicament for the treatment of bleedings due to an overdose of anticoagulants.
10 . A pharmaceutical composition comprising composition recited in any one of claims 1 to 5 , and an excipient and/or a pharmaceutically acceptable carrier.